Billy Hebert
Nurse Practitioner · Thibodaux, LANPI 1720446024
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,748 of the $8,442 with a category attached, or 68.1%. 32 manufacturers reported payments, led by Penumbra, Inc. at 48.7% of the total. 2025 is the largest year on record at $3,221, 3.7 times the $867 reported in 2021. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $35.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$4K
- Novartis$707
- Johnson & Johnson$347
- Amgen$326
- Kestra Medical Technology Services, Inc.$324
- Boston Scientific$303
- plus $2K from 26 others
What the payments were for
- Travel & lodging$2,60531%
- Food & beverage$5,74868%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 16 | $4,110 |
| Novartis | 49 | $707 |
| Johnson & Johnson | 25 | $347 |
| Amgen | 18 | $326 |
| Kestra Medical Technology Services, Inc. | 10 | $324 |
| Boston Scientific | 15 | $303 |
| Boehringer Ingelheim | 17 | $291 |
| Pfizer | 10 | $202 |
| Abbott | 6 | $192 |
| Abiomed | 6 | $191 |
| E.r. Squibb & Sons, L.L.C. | 4 | $178 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $172 |
| Esperion Therapeutics, Inc. | 8 | $122 |
| Actelion Pharmaceuticals US, Inc. | 3 | $114 |
| Bayer | 5 | $111 |
| Medtronic | 3 | $106 |
| Merck | 5 | $87 |
| Regeneron Healthcare Solutions, Inc. | 4 | $84 |
| Alnylam Pharmaceuticals Inc. | 4 | $72 |
| Scpharmaceuticals Inc. | 4 | $65 |
| Cardiva Medical, Inc. | 3 | $61 |
| Bard Peripheral Vascular, Inc. | 2 | $40 |
| AstraZeneca | 3 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Contego Medical, Inc | 1 | $24 |
| Terumo Medical Corporation | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Atricure, Inc. | 1 | $23 |
| Inari Medical, Inc. | 1 | $20 |
| Acacia Pharma Inc | 1 | $19 |
| Itamar Medical Inc | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$2,204
- RUBY Coil$1,690
- Assure WCD$148
- CAMZYOS$125
How this compares
$8,442 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $105,599 |
| EntrestoSacubitril/Valsartan | 72 | $63,890 |
| Repatha SureclickEvolocumab | 32 | $25,565 |
| FarxigaDapagliflozin Propanediol | 24 | $17,164 |
| BrilintaTicagrelor | 15 | $6,874 |
| NexletolBempedoic Acid | 14 | $6,514 |
| CorlanorIvabradine Hcl | 11 | $6,257 |
| VascepaIcosapent Ethyl | 11 | $3,992 |
| Metoprolol Succinate | 276 | $3,014 |
| Ranolazine ErRanolazine | 44 | $2,982 |
| Nifedipine ErNifedipine | 191 | $2,585 |
| Nebivolol Hcl | 43 | $2,466 |
| Clonidine | 14 | $1,640 |
| Rosuvastatin Calcium | 188 | $1,349 |
| ClopidogrelClopidogrel Bisulfate | 152 | $1,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $202 | $105,599129 claims |
| NovartisEntresto | $707 | $63,89072 claims |
| AstraZenecaFarxiga, Brilinta | $36 | $24,03839 claims |
| Esperion Therapeutics, Inc.Nexletol | $122 | $6,51414 claims |
| AmgenCorlanor | $326 | $6,25711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in Thibodaux
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
- Ellen GentileWest Monroe$31K
- Reghan LittlepageAlexandria$24K
- April WoodrowOpelousas$24K
- Amanda EstapaHammond$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.